BioSpace News Archive

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the fourth quarter and year ended December 31, 2020.

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, reported that on March 1, 2021, the Company granted non-qualified stock options to purchase an aggregate of 54,250 shares of the Company’s common stock to seven newly hired employees.

Conformis, Inc. announced financial results for the fourth quarter and year ended December 31, 2020.

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced that it has commenced an underwritten public offering of shares of its common stock.

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the second quarter of 2021.

Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today reported annual financial results for the year ended December 31, 2020 and provided a corporate overview / business update.

One course of teplizumab delayed insulin dependence by approximately three years and improved beta cell function in at-risk (Stage 2) type 1 diabetes patients

BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced that Rob Williamson, President and CEO, will present a company overview and will participate virtually in the following investor conferences

Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, announced that it has granted inducement stock options to purchase an aggregate of 38,250 shares of its common stock to six new employees.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its fourth quarter 2020 financial results will be released after the markets close on Wednesday, March 10th.